Regulus Therapeutics Stock Current Valuation
| RGLS Stock | USD 1.61 0.03 1.83% |
Valuation analysis of Regulus Therapeutics helps investors to measure Regulus Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to drop to -0.1 in 2024. Enterprise Value Multiple is likely to drop to -0.1 in 2024. Fundamental drivers impacting Regulus Therapeutics' valuation include:
Price Book 1.2149 | Enterprise Value 18.6 M | Enterprise Value Ebitda 0.5691 | Price Sales 7.4299 | Enterprise Value Revenue 0.6573 |
Undervalued
Today
Please note that Regulus Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of Regulus Therapeutics is based on 3 months time horizon. Increasing Regulus Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Regulus stock is determined by what a typical buyer is willing to pay for full or partial control of Regulus Therapeutics. Since Regulus Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Regulus Stock. However, Regulus Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.61 | Real 2.71 | Target 6.25 | Hype 1.61 | Naive 1.7 |
The intrinsic value of Regulus Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Regulus Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Regulus Therapeutics helps investors to forecast how Regulus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Regulus Therapeutics more accurately as focusing exclusively on Regulus Therapeutics' fundamentals will not take into account other important factors: Regulus Therapeutics Company Current Valuation Analysis
Regulus Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Regulus Therapeutics Current Valuation | 18.63 M |
Most of Regulus Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Regulus Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Regulus Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Regulus Therapeutics is extremely important. It helps to project a fair market value of Regulus Stock properly, considering its historical fundamentals such as Current Valuation. Since Regulus Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Regulus Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Regulus Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Regulus Therapeutics has a Current Valuation of 18.63 M. This is 99.87% lower than that of the Biotechnology sector and 99.6% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.89% higher than that of the company.
Regulus Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regulus Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Regulus Therapeutics could also be used in its relative valuation, which is a method of valuing Regulus Therapeutics by comparing valuation metrics of similar companies.Regulus Therapeutics is currently under evaluation in current valuation category among its peers.
Regulus Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Regulus Therapeutics from analyzing Regulus Therapeutics' financial statements. These drivers represent accounts that assess Regulus Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Regulus Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 15.4M | 47.2M | 27.4M | 20.9M | 24.0M | 22.8M | |
| Enterprise Value | (4.1M) | 20.8M | (25.9M) | 3.0M | 3.4M | 3.2M |
Regulus Fundamentals
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.42 | ||||
| Current Valuation | 18.63 M | ||||
| Shares Outstanding | 65.5 M | ||||
| Shares Owned By Insiders | 1.69 % | ||||
| Shares Owned By Institutions | 88.29 % | ||||
| Number Of Shares Shorted | 1.64 M | ||||
| Price To Earning | (0.69) X | ||||
| Price To Book | 1.21 X | ||||
| Price To Sales | 7.43 X | ||||
| Gross Profit | (18.41 M) | ||||
| EBITDA | (30.88 M) | ||||
| Net Income | (30.04 M) | ||||
| Cash And Equivalents | 47.53 M | ||||
| Cash Per Share | 3.25 X | ||||
| Total Debt | 2.39 M | ||||
| Debt To Equity | 0.17 % | ||||
| Current Ratio | 8.82 X | ||||
| Book Value Per Share | 1.32 X | ||||
| Cash Flow From Operations | (26.77 M) | ||||
| Short Ratio | 3.63 X | ||||
| Earnings Per Share | (1.02) X | ||||
| Price To Earnings To Growth | (0.04) X | ||||
| Target Price | 10.33 | ||||
| Number Of Employees | 32 | ||||
| Beta | 1.63 | ||||
| Market Capitalization | 107.42 M | ||||
| Total Asset | 30.75 M | ||||
| Retained Earnings | (513.21 M) | ||||
| Working Capital | 19.67 M | ||||
| Current Asset | 134.26 M | ||||
| Current Liabilities | 12.63 M | ||||
| Net Asset | 30.75 M |
About Regulus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Regulus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regulus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regulus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Regulus Stock Analysis
When running Regulus Therapeutics' price analysis, check to measure Regulus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regulus Therapeutics is operating at the current time. Most of Regulus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Regulus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regulus Therapeutics' price. Additionally, you may evaluate how the addition of Regulus Therapeutics to your portfolios can decrease your overall portfolio volatility.